Evidence map›Paper›PMID 39557718›Full record

ArticleAnnals of surgical oncology2025

Role of Adjuvant Chemotherapy After Surgical Resection of Paraaortic Lymph Node Metastasis from Colorectal Cancer-A Multicenter Retrospective Study.

Hiroaki Nozawa, Sono Ito, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Yuichiro Yokoyama, Shinichi Yamauchi, Yusuke Kinugasa, Yoichi Ajioka, Soichiro Ishihara

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hiroaki NozawaDepartment of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. hiroanozawa@yahoo.co.jp.ORCID http://orcid.org/0000-0002-7891-5986
Sono ItoGastrointestinal Surgery, Institute of Science Tokyo, Tokyo, Japan.
Kazuhito SasakiDepartment of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Koji MuronoDepartment of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Shigenobu EmotoDepartment of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yuichiro YokoyamaDepartment of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Shinichi YamauchiGastrointestinal Surgery, Institute of Science Tokyo, Tokyo, Japan.
Yusuke KinugasaGastrointestinal Surgery, Institute of Science Tokyo, Tokyo, Japan.
Yoichi AjiokaDivision of Molecular and Diagnostic Pathology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
Soichiro IshiharaDepartment of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSurgical removal of metastasized paraaortic lymph nodes (PALNs) can prolong the survival of certain patients with colorectal cancer (CRC). However, the role of postoperative chemotherapy in such patients remains unknown. PATIENTS AND

methodsThis multicenter retrospective study examined 97 patients with PALN metastasis from CRC who underwent surgical resection at 36 centers in Japan between 2010 and 2015. On the basis of adjuvant chemotherapy (AC) after the lymphadenectomy, patients were classified into non-AC and AC groups (27 and 70 patients, respectively). After the exclusion of patients receiving irinotecan, the latter group was further categorized into 5-fluorouracil (5-FU) and oxaliplatin (L-OHP) subgroups (14 and 52 patients, respectively) according to the use of L-OHP. Background characteristics and postoperative survival were compared among the groups.

resultsMarked differences were not seen in background characteristics, except for neoadjuvant treatment, between the non-AC and AC groups. The AC group exhibited better recurrence-free survival (RFS; p = 0.009) and overall survival (OS; p = 0.040 by the Wilcoxon test) than the non-AC group. However, RFS and OS of the 5-FU group did not differ from those of the L-OHP group (p = 0.73 and p = 0.92 by the Wilcoxon test, respectively).

conclusionsAC may be associated with improved prognosis of patients after the removal of PALN metastasis from CRC, but L-OHP did not offer additional survival benefits. Prospective studies comparing non-AC with 5-FU- and L-OHP-based AC are needed to confirm these findings.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsLymph Node ExcisionLymph NodesNeoplasm Recurrence, LocalAdultAgedChemotherapy, AdjuvantFemaleFluorouracilFollow-Up StudiesHumansLymphatic MetastasisMaleMiddle AgedOrganoplatinum CompoundsFluorouracilOrganoplatinum CompoundsOxaliplatin5-fluorouracilAdjuvant chemotherapyColorectal cancerOxaliplatinParaaortic lymph node metastasis

Identifiers

PMID39557718
PMCPMC11882702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.